Jim Cramer’s Charitable Trust has decided to purchase 100 shares of Abbott Laboratories at approximately $108.26, increasing its total shares to 800 and raising its weighting in the company to 2.8%. Despite Abbott reporting better-than-expected first-quarter earnings, the stock is trading lower in the premarket, providing an opportunity for the trust to add to its position for the third time in recent weeks. The company’s worldwide sales for the first quarter increased by 2.2% year over year to $10 billion, exceeding Wall Street estimates. Organic sales growth for the base business, excluding Covid-19 testing-related sales, continued to show positive momentum, with double-digit growth for the fifth consecutive quarter across various segments.
Abbott also surpassed analyst expectations on the bottom line, with adjusted earnings per share of $0.98 compared to estimates of $0.95. Following the strong quarter, Abbott raised the low end of its full-year adjusted EPS and organic sales outlooks, indicating positive prospects for the company’s future performance. Despite these positive developments, Abbott’s stock has seen a slight decline year to date, presenting an opportunity for the Charitable Trust to capitalize on the discrepancy between strong performance and market perception. The trust views the weakness in the stock price as a chance to increase its position in Abbott, as it believes in the company’s underlying business performance and potential for growth.
By focusing on Abbott’s underlying business performance and excluding Covid-19 testing-related sales, the Charitable Trust aims to assess the company’s actual operational strength and growth prospects. The trust believes that improvements in the underlying business are more significant indicators of Abbott’s long-term performance than short-term fluctuations due to pandemic-related sales. Despite the stock market’s lack of recognition for the company’s strong performance, the trust remains confident in Abbott’s ability to deliver positive results and increase shareholder value. The decision to increase their stake in Abbott aligns with the trust’s long-term investment strategy and faith in the company’s overall trajectory.
As a subscriber to the CNBC Investing Club with Jim Cramer, members receive trade alerts before Jim executes any trades in his charitable trust’s portfolio. Jim typically waits 45 minutes after sending a trade alert before buying or selling a stock, and 72 hours if the stock has been discussed on CNBC TV. It is important to note that the information provided in connection with the Investing Club is subject to terms and conditions, privacy policy, and disclaimer. No fiduciary obligation exists by receiving information from the Investing Club, and specific outcomes or profits are not guaranteed. Subscribers should carefully consider their investment decisions based on the information provided and the market conditions.
